{"id":"NCT00534248","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","officialTitle":"A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2007-09-24","resultsPosted":"2011-05-02","lastUpdate":"2017-04-12"},"enrollment":22439,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Shingles"],"interventions":[{"type":"BIOLOGICAL","name":"Zoster Vaccine, Live (Zostavax™)","otherNames":["V211","Zostavax™"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"Zostavax™","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.","primaryOutcome":{"measure":"Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group","timeFrame":"2 Years","effectByArm":[{"arm":"Zostavax™","deltaMin":1.994,"sd":null},{"arm":"Placebo","deltaMin":6.596,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24823623","23908486","22291101"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":243,"n":11094},"commonTop":["Injection site pain","Injection site erythema","Injection site swelling","Headache","Injection site pruritus"]}}